Postsorafenib Systemic Treatments for Hepatocellular Carcinoma: Questions and Opportunities After the Regorafenib Trial

Future Oncology- United Kingdom

doi 10.2217/fon-2017-0166

Full Text

Abstract

Available in

Date

Authors

Publisher

Future Medicine Ltd

Related search

New Systemic Treatments in Advanced Hepatocellular Carcinoma

Liver Transplantation
HepatologyTransplantationSurgery
2019English

Successful Treatment of Hepatocellular Carcinoma With Regorafenib After Sorafenib-Induced Hypersensitivity

Internal Medicine
Internal MedicineMedicine
2019English

Locoregional and Systemic Therapy for Hepatocellular Carcinoma

Journal of Gastrointestinal Oncology
OncologyGastroenterology
2017English

Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma After Curative Resection

Frontiers in Physiology
Physiology
2017English

Answers and Remaining Questions Regarding Systemic Treatments for Breast Cancer in the Elderly

European Oncology and Haematology
OncologyHematology
2007English

Pcn17 - Indirect Treatment Comparisons of Nivolumab Versus Regorafenib, Cabozantinib and Best Supportive Care After Treatment With Sorafenib for Hepatocellular Carcinoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Network Meta-Analysis of Treatments for Unresectable Hepatocellular Carcinoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Systemic Immune-Inflammation Index Predicts Prognosis of Patients After Curative Resection for Hepatocellular Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2014English

Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma

Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy